Ascletis transitions to oral delivery for obesity treatment with US Phase I trial initiation of ASC36
Executive summary: Ascletis has started a Phase I clinical trial in the US for ASC36, an oral tablet targeting obesity via amylin receptor agonism. The development of an oral version of peptide-based obesity treatments represents a significant potential shift in patient compliance and market competition against existing injectable GLP-1 therapies.
Who is involved: Ascletis (developer), US clinical investigators, and potential obesity patients.
Likely next: The release of initial safety and pharmacokinetic data from the Phase I human subjects.
Ascletis has officially launched a Phase I clinical study in the United States to evaluate ASC36, an oral amylin receptor peptide agonist aimed at obesity management. This move highlights a strategic shift toward oral bioavailability, leveraging proprietary transport enhancement technology to move beyond injectable formats. The study follows previous developments regarding subcutaneous formulations, indicating an expanding clinical pipeline for the company.
What's next — scenarios
Base: Successful oral bioavailability proof (50%)
ASC36 demonstrates safe and effective oral absorption, advancing to Phase II.
- Phase I pharmacokinetic data confirming steady-state levels in humans
Upside: Superiority over injectables (20%)
Data suggests oral ASC36 provides comparable efficacy to injectables with fewer side effects, driving massive investment.
- Clinical data showing high patient compliance profiles
Downside: Absorption failure (30%)
Oral bioavailability fails to meet therapeutic thresholds, halting the oral program.
- Phase I reports showing inadequate plasma concentration in humans
What to watch
- Phase I safety and pharmacokinetic data release
- Updates on Ascletis' proprietary Peptide Oral Transport ENhancement Technology performance
Timeline
- — Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity (PR Newswire)
- — Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection... (PR Newswire)
Analysis — what this means
Likely next events
- Completion of Phase I dosing cohorts (unspecified date)
Sectors affected
- Pharmaceuticals
- Obesity treatment/Metabolic health
- Drug delivery technology
Regulatory implications
- FDA oversight of Phase I safety protocols for new peptide agonists
Historical parallels
- Development of oral GLP-1 agonists by major pharmaceutical competitors